Mogrify

Milton, United Kingdom

Mogrify’s mission is to transform the lives of patients through the development of a novel class of in vivo reprogramming therapies, initially addressing indications in ophthalmology, otology and metabolic and other areas of degenerative disease. Using its proprietary suite of platform technologies to systematically identify the key transcriptomic and epigenetic switches required to drive direct cellular reprogramming, the Company is able to generate the functional cell types (in vivo or ex vivo) required to address diseases with a high unmet clinical need. MOGRIFY® is a direct cellular reprogramming platform, which leverages transcriptomic data to identify optimal combinations of transcription factors for the conversion, via enhanced forward reprogramming or transdifferentiation, of any cell type into any other cell type. epiMOGRIFY® is a cell identity platform, which leverages epigenetic data to identify optimal combinations of transcription factors or growth factors required to main